LLY

987.47

-1.05%↓

JNJ

203.85

+0.62%↑

ABBV

223.03

+0.43%↑

UNH

324.34

+0.05%↑

AZN

89.95

-0.53%↓

LLY

987.47

-1.05%↓

JNJ

203.85

+0.62%↑

ABBV

223.03

+0.43%↑

UNH

324.34

+0.05%↑

AZN

89.95

-0.53%↓

LLY

987.47

-1.05%↓

JNJ

203.85

+0.62%↑

ABBV

223.03

+0.43%↑

UNH

324.34

+0.05%↑

AZN

89.95

-0.53%↓

LLY

987.47

-1.05%↓

JNJ

203.85

+0.62%↑

ABBV

223.03

+0.43%↑

UNH

324.34

+0.05%↑

AZN

89.95

-0.53%↓

LLY

987.47

-1.05%↓

JNJ

203.85

+0.62%↑

ABBV

223.03

+0.43%↑

UNH

324.34

+0.05%↑

AZN

89.95

-0.53%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

102.24 -1.05

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

99.21

Максимум

103.2

Ключови измерители
By Trading Economics
Приходи	-6.3M -53M
Продажби	2.8M 51M
EPS	-0.82
Марж на печалбата	-103.131
Служители	283
EBITDA	-7.6M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+19.24% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-535M 7B
Предишно отваряне	103.29
Предишно затваряне	102.24

Настроения в новините

By Acuity

44%

56%

168 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.12.2025 г., 22:13 ч. UTC

Печалби

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9.12.2025 г., 21:40 ч. UTC

Печалби

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9.12.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9.12.2025 г., 16:57 ч. UTC

Значими двигатели на пазара

Clear Secure Rises on Medicare Identity Verification Contract

9.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9.12.2025 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings Stake in Lenovo Now at 32.34%

9.12.2025 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9.12.2025 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9.12.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9.12.2025 г., 22:42 ч. UTC

Печалби

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9.12.2025 г., 20:28 ч. UTC

Пазарно говорене

Oil Futures Decline for Second Straight Session -- Market Talk

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Reports Voting Results From Special Meeting of Hldrs

9.12.2025 г., 20:26 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9.12.2025 г., 20:21 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9.12.2025 г., 19:52 ч. UTC

Печалби

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9.12.2025 г., 19:17 ч. UTC

Печалби

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.12.2025 г., 17:11 ч. UTC

Печалби

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

19.24% нагоре

12-месечна прогноза

Среден 125.42 USD 19.24%

Висок 142 USD

Нисък 110 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

168 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.